| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T10 |
0-99 |
Sentence |
denotes |
We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. |
| T11 |
100-176 |
Sentence |
denotes |
We performed a meta-analysis of 47 studies including 10,890 unique patients. |
| T12 |
177-380 |
Sentence |
denotes |
Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). |
| T13 |
381-428 |
Sentence |
denotes |
Most studies reported on hospitalized patients. |
| T14 |
429-614 |
Sentence |
denotes |
The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). |
| T15 |
615-848 |
Sentence |
denotes |
When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). |
| T16 |
849-891 |
Sentence |
denotes |
Isolated GI symptoms were reported rarely. |
| T17 |
892-999 |
Sentence |
denotes |
We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19. |
